Xu et al. developed bMSN embedding TLR9 agonist CpG and Ce6 for tumor PDIT, which achieved a superior antitumor potency in PDIT by releasing immunostimulant CpG and antigenic peptides after breaking disulfide bonds 42. This evidence concerns the gene TLR9 and neoplasm.